Based on a prospective, longitudinal patient survey of 699 adult patients who had not been treated with DUPIXENT prior to this study. Surveys were completed at baseline (prior to DUPIXENT treatment) and at Months 1, 2, 3, 6, 9, 12, 33 and 48 after initiation of DUPIXENT. Data are from an interim analysis of patients who had completed surveys at 1 month (n=631) through 48 months (n=353). Patient-reported satisfaction with current atopic dermatitis treatment was evaluated using the question “How satisfied are you with your current treatment(s) for atopic dermatitis?” with responses on a 7-point Likert scale that ranged from “extremely satisfied” to “extremely dissatisfied.”14-16
Limitations of analysis:
The survey data were collected from patients who enrolled in the DUPIXENT patient support program, and these patients may have different perceptions of DUPIXENT vs those who did not enroll. Patients who continue to respond to long-term surveys may be self-selecting for favorable effectiveness and safety. Only 50.6% of patients who responded at baseline responded to the survey at Month 48, which could have led to survivor bias. There was also potential for recall bias because outcomes were self-reported. As observed data may bias results. Safety and tolerability data were not collected.14-16